VirologyMicrobiologyPeer-reviewed journal article
A high-throughput, microplate reader-based method to monitor in vitro HIV latency reversal in the absence of flow cytometry
Chantal Emade Nkwelle, Unique Stephens, Kimberly Liang, Joel A. CasseliD, Joseph M. SalvinoiD, Luis J. MontaneriD, Roland N. NdipiD, Seraphine Nkie EsemuiD, Fidele Ntie‐KangiD, Ian TietjeniD
Abstract
J-Lat cells are derivatives of the Jurkat CD4+ T cell line that contain a non-infectious, inducible HIV provirus with a GFP tag. While these cells have substantially advanced our understanding of HIV latency, their use by many laboratories in low and middle-income countries is restricted by limited access to flow cytometry. To overcome this barrier, we describe a modified J-Lat assay using a standard microplate reader that detects HIV-GFP expression following treatment with latency-reversing agents (LRAs). We show that HIV reactivation by control LRAs like prostratin and romidepsin is readily detected with dose dependence and with significant correlation and sensitivity to standard flow cytometry. For example, 10 {micro}M prostratin induced a 20.1 {+/-} 3.3-fold increase in GFP fluorescence in the microplate reader assay, which corresponded to 64.2 {+/-} 5.0% GFP-positive cells detected by flow cytometery. Similarly, 0.3 {micro}M prostratin induced a 1.7 {+/-} 1.2-fold increase compared to 8.7 {+/-} 5.7% GFP-positive cells detected. Using this method, we screen 79 epigenetic modifiers and identify molibresib, quisinostat, and CUDC-101 as novel LRAs. This microplate reader-based method offers accessibility to researchers in resource-limited regions to work with J-Lat cells and more actively participate in global HIV cure research efforts. HighlightsO_LIJ-Lat T-cell lines are important to HIV cure research but require flow cytometry C_LIO_LIWe describe a method to work with J-Lat cells using a standard microplate reader C_LIO_LIThis assay can detect control LRAs similar to flow cytometry and discover new LRAs C_LIO_LIThis assay allows low-resourced laboratories to contribute to HIV cure research C_LI
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 1
- FWCI
- 0.34
- Field percentile
- 45th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Automated microarray for single-cell sorting and collection of lymphocytes following HIV reactivation
B. Cortes-Llanos, V. Jain, … N. Allbritton·bioRxiv·Feb 2, 2023
- Development of an HIV reporter virus that identifies latently infected CD4+ T cells
E. H. Kim, L. Manganaro, … V. Simon·bioRxiv·Jan 17, 2022
- A highly stringent high-throughput screening assay for identifying transcription-modulating agents of HIV-1 latency
Chhavi Saini, Agnita Roychowdhury, … Udaykumar Ranga·bioRxiv·Jan 11, 2026
- A widely-distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro
K. Matsuda, S. Islam, … K. Maeda·Cell Reports MethodsPeer-reviewed·Dec 1, 2021
- Identification of Celastrol as a novel HIV-1 Latency Reversal Agent by an Image-Based Screen
A. P. Rice, H. Liu, … B. Nikolai·bioRxiv·Dec 17, 2020
- Detecting sources of immune activation and viral rebound in HIV infection
S. Wietgrefe, L. Duan, … A. T. Haase·bioRxiv·Jun 8, 2022